Freely Filtered 033: The Roxadustat Statistics shenanigans

from Freely Filtered, a NephJC Podcast · host joel topf

Episode metadata supplied by the publisher feed · Published Apr 20, 2021

Embed this episode

Attribution link and audio player

What this episode covers

On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Freely Filtered 033: The Roxadustat Statistics shenanigans

0:00 1:07:12

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Freely Filtered, a NephJC Podcast?

This episode is 1 hour and 7 minutes long.

When was this Freely Filtered, a NephJC Podcast episode published?

This episode was published on April 20, 2021.

Can I download this Freely Filtered, a NephJC Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!